Taiho Pharmaceutical Co., Ltd.
4 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 14 name spellings.
21
Ending by 2030
Jun 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 3 fees due Nov 26 to 30, 2026 · next Nov 26
- 3 fees due Dec 18 to 25, 2026 · next Dec 18
- 3 fees due Jan 4 to 18, 2027 · next Jan 4
- 3 fees due Feb 6 to 20, 2027 · next Feb 6
- 1 fee due Mar 24, 2027The maintenance fee for Pyrrolo[2,3-d]pyrimidine compound or salt thereof (US 10,421,760) comes due Mar 24, 2027. Unpaid by Sep 24, 2027, it lapses early.
- 7 fees due Apr 6 to 29, 2027 · next Apr 6
- 1 fee due May 17, 2027The maintenance fee for Nanoparticles containing pH-responsive peptide (US 9,186,389) comes due May 17, 2027. Unpaid by Nov 17, 2027, it lapses early.
- 1 fee due Jun 5, 2027The maintenance fee for Pharmaceutical composition including sodium alkyl sulfate (US 11,833,151) comes due Jun 5, 2027. Unpaid by Dec 6, 2027, it lapses early.
- 6 fees due Jul 2 to 30, 2027 · next Jul 2
- 3 fees due Sep 1 to 5, 2027 · next Sep 1
- 1 fee due Oct 23, 2027The maintenance fee for Combination Decitabine and Cedazuridine Solid Oral Dosage Forms (US 11,963,971) comes due Oct 23, 2027. Unpaid by Apr 24, 2028, it lapses early.
- 1 fee due Nov 7, 2027The maintenance fee for Preparation and composition for treatment of malignant tumors (US 11,975,002) comes due Nov 7, 2027. Unpaid by May 8, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 20, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,440,675 | Potentiator of radiation therapy In force · From the USPTO record | In force | From the USPTO record | |
| US 8,148,381 | Potentiator of radiation therapy In force · From the USPTO record | In force | From the USPTO record | |
| US 8,618,075 | Certain Compounds, Compositions and Methods In force · High confidence | In force | High confidence | |
| US 8,951,987 | Certain Compounds, Compositions and Methods In force · High confidence | In force | High confidence | |
| US 9,567,363 | Certain Compounds, Compositions and Methods In force · Medium confidence | In force | Medium confidence | |
| US 8,410,096 | Antitumor agent, kit and method of treating cancer In force · From the USPTO record | In force | From the USPTO record | |
| US RE46,284 | Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor In force · From the USPTO record | In force | From the USPTO record | |
| US 8,530,490 | Uracil compound or salt thereof having human deoxyuridine triphosphatase inhibitory activity In force · From the USPTO record | In force | From the USPTO record | |
| US 8,304,427 | Acylthiourea compound or salt thereof, and use thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 9,062,035 | Piperazine compound capable of inhibiting prostaglandin D synthase In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 145: 4 patents in force now held by others · 70 lapsed for an unpaid fee · 149 ended at full term · 2 surrendered on reissue. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
34 pending · 13 abandoned · 52 no status recorded